Latest Sexual dysfunction Stories

4 out of 5 female dialysis patients reported sexual dysfunction Highlights:     In the largest observational study of its kind, 84% of all women and 55% of sexually active women on hemodialysis experienced sexual problems.     Sexual dysfunction was reported more often by women who were older, were less educated, had signs of depression, had reached menopause, had diabetes, and took diuretic therapy, or 'water pills.' Other studies indicate that sexual dysfunction is also...

GREENWOOD VILLAGE, Colo., April 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it reached agreement with the Therapeutic Goods Administration (TGA), Canberra, Australia, on a plan of drug manufacture and quality control for Zertane(TM)( )and the overall plan for the preparation of Common Technical...

Goldlite Hypnosis Institute Recently Helped Steve Overcome Sexual Dysfunction Newport Beach, CA (PRWEB) March 30, 2012 Steve Recently Overcome Sexual Dysfunction with the Help of Goldlite Hypnosis Institute Steve had a premature ejaculation problem for a long time. Things were getting worse slowly. His wife was not happy with that. She kept on nagging him to get help. Finally couple months ago he decided to use Hypnotherapy and hoped that will help him. Although he was suspicious and had...

First national survey of OB-GYN sex history screening practices confirms narrow focus How often does your doctor ask about your sexual life? Unfortunately, the answer may be: not often enough. Leaving the subject off the check-up checklist could mean missing an important link to overall wellness. Results of a comprehensive national survey of U.S. obstetrician-gynecologists regarding communication with patients about sex have found that too often doctors aren't having "the talk" with...

GREENWOOD VILLAGE, Colo. and GOIANIA, GOIAS, Brazil, March 22, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), and FBM Industria Farmaceutica Ltda ("FBMFarma"), a member of the HOSPFAR Group that manufactures, imports and distributes pharmaceuticals in Brazil, today announced a license and distribution agreement providing...

Erectile dysfunction is a common problem for men who have diabetes, and Advanced Male Medical Center, offering treatments in the San Francisco area for erectile dysfunction and premature ejaculation, features solutions for patients to get their sex life back. San Francisco, CA (PRWEB) March 15, 2012 San Francisco male impotence specialist, Advanced Male Medical Center, specializing in removing the difficulties that keep men from having a sex life, understands that diabetics often...

CRANBURY, N.J., March 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced it has completed enrollment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD). Over 400 premenopausal women, diagnosed with female sexual arousal disorder, hypoactive sexual desire disorder or both, have been enrolled in the study. Patients, who will undergo 16 weeks of treatment, will be...

JERSEY CITY, N.J., March 8, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc., a developer of therapeutics for disorders of women's sexual health, announced today an executive management addition and Scientific Advisory Board appointment to strengthen and expand the Company's leadership, as follows: Robert E. Pyke, MD, PhD, a member of the S1 Advisory Board of Directors since October 2011 was appointed as the Company's Chief Medical Officer. Molly A. Katz, MD was appointed as a...

Leading organization celebrates 15th annual recognition effort honoring women and girls with painful condition The Endometriosis Research Center (ERC) is pleased to once again honor those with endometriosis through the organization’s 15th annual “Awareness Month” recognition.  Often stigmatized as merely “killer cramps,” endometriosis is a poorly-understood disease characterized by pelvic pain, painful menstruation, infertility and pregnancy loss, pain with sexual activity,...

JERSEY CITY, N.J., Feb. 21, 2012 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD). Lorexys' clinical development plan is based on pharmacokinetic and safety data...